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and Instituto de Medicina Tropical, University of São Paulo, BrazilAbstractTreatment of Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae infections (KPC-EI) remains a challenge. Combined therapy
has been proposed as the best choice, but there are no clear data showing which combination therapy is superior. Our aim was to evaluate
the effectiveness of antimicrobial regimens for treating KPC-EI. This was a retrospective cohort study of KPC-EI nosocomial infections (based
on CDC criteria) between October 2009 and June 2013 at three tertiary Brazilian hospitals. The primary outcomes were the 30-day
mortality for all infections and the 30-day mortality for patients with bacteraemia. Risk factors for mortality were evaluated by comparing
clinical variables of survivors and nonsurvivors. In this study, 118 patients were included, of whom 78 had bacteraemia. Catheter-related
bloodstream infections were the most frequent (43%), followed by urinary tract infections (n = 27, 23%). Monotherapy was used in 57
patients and combined treatment in 61 patients. The most common therapeutic combination was polymyxin plus carbapenem 20 (33%).
Multivariate analysis for all infections (n = 118) and for bacteremic infections (n = 78) revealed that renal failure at the end of treatment,
use of polymyxin and older age were prognostic factors for mortality. In conclusion, polymyxins showed suboptimal efﬁcacy and
combination therapy was not superior to monotherapy.
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E-mail: maura.oliveira@hc.fm.usp.brIntroductionKlebsiella pneumoniae carbapenemase (KPC)-producing bacte-
rium was ﬁrst described in 2001 in North Carolina, USA. It isClinical Microbiology and Infection © 2014 European Society of Can Ambler molecular class A enzyme, which hydrolyses all
β-lactams including carbapenems. It has been found in many
Gram-negative bacteria all over the world and has become
endemic in some countries [1]. In Brazil, the ﬁrst detection of
KPC-2-producing K. pneumoniae strains occurred in 2006 [2];
now it has become an important agent of hospital-acquired
infection.
Treatment of KPC-producing Enterobacteriaceae infections
(KPC-EI) remains a challenge. They are usually susceptible only
to aminoglycosides, tigecycline, and polymyxins. Combined
therapy has been proposed as the best choice, but there are no
clear data that show which combination therapy is superior [1].Clin Microbiol Infect 2015; 21: 179.e1–179.e7
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antimicrobial regimens for treating infections caused by KPC-
producing Enterobacteriaceae.Patients and methodsWe performed a retrospective review of patients who had
nosocomial KPC-EI (infections that occurred 48 hours or more
after admission) between October 2009 and June 2013 [3]. The
study was conducted at three tertiary Brazilian hospitals:
Hospital das Clínicas (teaching hospital associated with the
University of São Paulo with 1000 beds), Instituto do Câncer do
Estado de São Paulo (oncology teaching hospital associated with
the University of São Paulo with 465 beds) and Hospital
Municipal Jose de Carvalho Florence (municipal hospital with
400 beds).
Patients were identiﬁed by the infection control department
databases, and the diagnoses of infection were based on CDC
criteria [3] plus the isolation of KPC-producing Enter-
obacteriaceae. Identiﬁcation and susceptibility testing was per-
formed by an automated method (bioMerieux Vitek 2,
Hazelwood, MO, USA). We used Clinical and Laboratory
Standards Institute (CLSI) breakpoints (isolates were consid-
ered resistant to meropenem or imipenem if minimum inhibi-
tory concentration (MIC) was 4 μg/mL according to 2010
CLSI revised breakpoints). Ertapenem-resistant isolates (if MIC
was 2 μg/mL based on the revised 2010 CLSI breakpoints) [4]
were submitted to polymerase chain reaction to detect the
blaKPC gene [5], and only isolates carrying blaKPC carbape-
nemase genes were included.
We included cases treated for at least 48 hours, and only the
ﬁrst treatment was evaluated. Patients with polymicrobial
Gram-negative infections were excluded.
The following variables were collected from patients’ re-
cords: date of admission to the hospital and to the unit where
the infection occurred; gender; age; presence of comorbidities;
severity of illness according to Acute Physiology and Chronic
Health Examination II score [6] at the time of patient’s admis-
sion to the unit; antibiotic use and invasive procedures during
the 10 days prior to the diagnosis of infection; surgery during
the 60 days previous to the diagnosis of infection; infection site;
date and site of isolation of KPC-producing Enterobacteriaceae,
antimicrobial drugs and dosage used to treat the KPC-EI;
concomitant nosocomial infections; concomitant use of other
antimicrobials.
The primary outcome was the 30-day mortality after the
isolation of KPC-producing Enterobacteriaceae for all infections
and for bacteraemia. Risk factors for mortality were evaluated
by comparing clinical variables of survivors and nonsurvivors.Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and InfectTreatment regimens were classiﬁed as monotherapy or
combination therapy (use of more than one antimicrobial drug
for Gram-negative bacteria).
Renal function during treatment was monitored by serum
creatinine levels. Renal toxicity was deﬁned as a twofold in-
crease in serum creatinine at any time during the treatment,
compared with the level at the start of therapy or an increase
by 1 mg/dL if initial creatinine was abnormal (higher than
1.4 mg/dL) [7]. We evaluated any neurological abnormality,
such as seizures, paresthesia, and altered mental status.
Neurotoxicity was deﬁned as the presence of these signs or
symptoms that were not related to any other neurologic
diagnosis. We monitored reports of skin rash and diarrhoea.
The study was approved by the Hospital Ethics Committee.
Statistical analysis was performed by using SPSS statistical
software (version 19, SPSS Inc., Chicago, IL, USA). Continuous
variables were compared using Student’s t test (for normally
distributed variables) or the Mann-Whitney U test (for non-
normally distributed variables). Categorical variables were
evaluated with the χ2 or 2-tailed Fisher exact test, as appro-
priate. Relative risks and 95% conﬁdence intervals were
calculated. Results were expressed as mean ± standard devia-
tion or median (range) (continuous variables), or as percentages
of the group from which they were derived (categorical vari-
ables). All p values were two-tailed, and a p value of 0.05 was
considered statistically signiﬁcant.
Multivariate analysis was used to identify independent risk
factors for mortality and was performed by step-wise binary
logistic regression. Variables with a p value of <0.10 in the
bivariate analyses were included as candidate variables. Final
model included variables with an adjusted p value of <0.05.ResultsDuring the study period there were 522 positive cultures for
KPC-producing Enterobacteriaceae: 341 were considered as
colonizers, 36 were treated for <48 hours, 12 had no medical
records available, nine were outpatients, and six were poly-
microbial. Thus, 118 patients were included, of whom 78 had
bacteraemia.
The main species identiﬁed was K. pneumoniae 108 (92%),
followed by Serratia marcescens (n = 6), Enterobacter cloacae
(n = 3), and Escherichia coli (n = 1). Mean time between hospital
admission and infection was 26 days, mean age of patients was
56 years, and previous renal impairment was present in 31%.
Forty-seven patients (40%) had 51 other infections during the
ﬁrst 10 days of treatment for KPC-EI, and 43 (84%) of these had
identiﬁed etiologic agents: 36 (77%) bacterial, 10 (21%) fungal,
and one viral.ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 179.e1–179.e7
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frequent at 43% (51/118), followed by urinary tract infections,
23% (27/118). Among bacteremic infections (n = 78), the di-
agnoses were: 65% catheter-related, 15% secondary to intra-
abdominal infections and 20% secondary to other infection
sites.
The mean duration of treatment was 14 days (range 3–64
days).
Monotherapy was used in 57 (48%) patients: carbapenem in
25, polymyxin in 21, aminoglycosides in nine and tigecycline in
two. Bacteremic infections were treated with monotherapy in
34 (44%) cases: 16 with carbapenem, 15 with polymyxin, two
with aminoglycosides and one tigecycline. Among the 16
bacteremic infections treated with carbapenem monotherapy,
six (37.5%) presented an MIC 2 mg/L for the carbapenem
they received and 12 (75%) survived.
Combined therapy was used in 61 (52%) patients; 36 (59%)
were treated with two drugs, 19 (31%) with three drugs, and 6
(10%) with four drugs. The most common combination was
polymyxin plus carbapenem: n = 20 (33%).
Among patients treated with polymyxins, 38 received coli-
stimethate (median and mean daily doses of colistin base were
150 mg and 176 mg, respectively). Thirty-four used polymyxin
B (median and mean daily doses, respectively, were 1 287 143
and 1 000 000 IU). Sixty-ﬁve isolates were tested for poly-
myxins; 18 (28%) presented MIC 2 mg/L.
The overall 30-day mortality was 45%. Bivariate analysis
including all infections and bacteremic infections revealed that
intensive care unit admission, use ofmechanical ventilation, onset
of renal failure during treatment, early beginning of treatment,
treatment with polymyxin, the three-drug combination
(polymyxin +meropenem + aminoglycoside) and treatment with
carbapenem combined with other drug were associated with
death, whereas urinary tract infections and treatment with car-
bapenem monotherapy were protective (Table 1).
Nephrotoxicity was the most common adverse event. It
occurred within the ﬁrst 7days of treatment in 14 patients (12%)
and was a later occurrence in 20 (17%) patients; nine (8%) pa-
tients required dialysis. Polymyxin was the antibiotic most
frequently associated with nephrotoxicity (39%) (p 0.003).
Cutaneous rash occurred in one case that was using
polymyxin + meropenem + tigecycline + aminoglycoside.
Neurotoxicity was reported for four cases: one received mon-
otherapy with polymyxin B, threewith polymyxin + carbapenem.
Diarrhoea occurred in six cases: two with imipenem mono-
therapy, one with amikacin + meropenem, one with
polymyxin + meropenem and two with polymyxin +
carbapenem + amikacin + tigecycline.
Factors associated with the 30-day mortality for bacteremic
infections in bivariate analysis were age, renal failure at the endClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Inof treatment, use of polymyxin, carbapenem combined with
other drug and treatment with three drugs (Table 2).
In the ﬁnal multivariate models, variables signiﬁcantly asso-
ciated with 30-day mortality were use of polymyxins, older age
and renal failure at the end of treatment (Table 3).DiscussionThe main ﬁnding of our study was that treatment with poly-
myxins was associated with a higher risk of dying, and this
probably was not due to nephrotoxicity, as the multivariate
analysis showed they were independent prognostic factors.
There are no well-designed clinical trials evaluating the efﬁcacy
of polymyxins for treating multi-drug-resistant Gram-negative
bacteria. Nevertheless, polymyxins are considered the mainstay
of therapy. For KPC-EI, in a recent study involving 107 cases,
the use of colistin was associated with higher clinical response
compared with the use of antimicrobial regimens without
colistin (62% vs. 43%; p 0.013) [8]. We can provide few hy-
potheses to explain the suboptimal efﬁcacy of polymyxins in
our study, which is contradictory with what has been previ-
ously published. First, dosage regimens of polymyxins are
currently being discussed. For colistin, different dosing regi-
mens are recommended for different pharmaceutical products
[9]. For polymyxin B, based on pharmacokinetic/pharmacody-
namic studies, some authors suggest not adjusting it in renal
failure [10]. Thus, the best dosage has not been established and
it is possible that our patients may have received suboptimal
doses. Another point that could explain the poor clinical efﬁ-
cacy of polymyxins in our study is resistance. Currently, there
are no CLSI recommendations for breakpoints for Enter-
obacteriaceae [4]. However “elevated” polymyxin MICs have
been reported to be associated with mortality by isolates of
K. pneumoniae [11]. Our case series involved 18 patients with
polymyxin MIC >2 mg/L, and although this variable was not
available for all patients, it was not associated with mortality in
the bivariate analysis. Another possible explanation is that
polymyxins are not as effective as carbapenems.
Surprisingly, in our study, combination therapy was not su-
perior to monotherapy. Two retrospective studies found that
combination therapy was superior to monotherapy. Daikos
et al. evaluated 205 bloodstream infections caused by carba-
penemase-producing Klebsiella pneumoniae (KPC and metallo-β
lactamase) [12] and Tumbarello et al. evaluated the treatment of
125 KPC infections and suggest that the best approach is the
use of a three-drug combination: polymyxin +
meropenem + tigecycline [13]. Of note, both studies included a
large proportion of patients treated with tigecycline mono-
therapy: 27 (38%) and 19 (15%), respectively. Tigecycline hasfectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 179.e1–179.e7
TABLE 1. Bivariate analysis of prognostic or risk factors for 30-day in-hospital mortality in patients with infections caused by KPC-
producing Enterobacteriaceae in three large teaching hospitals (2009–2013)
Nonsurvivorsa (n [ 53) Survivorsa (n [ 65) RR (95% CI) p
Age (years) 0.08
Mean (SD) 59.7 (16.1) 53 (19.5)
Median (range) 60 (12–88) 56 (1–87)
Female sex 28 (53) 28 (43) 1.19 (0.86–1.66) 0.29
Time between admission and infection (days) 0.55
Mean (SD) 30 (31) 24.9 (19.2)
Median (range) 31 (0–182) 20.5 (0–107)
Admission to ICU 32 (60) 25 (38.5) 1.50 (1.06–2.11) 0.02
APACHE II score (points) 18 (5.7) 16.7 (7) 0.16
Mean (SD) 18 (8–31) 16 (2–34)
Median (range)
APACHE II 17 points 29 (55) 30 (48) 1.14 (0.82–1.59) 0.45
Invasive procedures
Mechanical ventilation 27 (51) 18 (28) 1.61 (1.08–2.39) 0.01
Central venous catheter 36 (68) 46 (71) 0.94 (065–1.35) 0.74
Urinary catheter 35 (66) 34 (52) 1.28 (0.93–1.77) 0.13
Previous surgery 24 (45) 22 (34) 1.25 (0.87–1.78) 0.21
Organ solid transplantation 10 (19) 7 (11) 1.40 (0.77–2.52) 0.21
Hematopoietic stem cell transplantation 4 (7.5) 5 (8) 0.99 (0.54–1.82) 1.00
Cancer 28 (53) 25 (38.5) 1.30 (0.92–1.84) 0.12
Diabetes mellitus 12 (23) 9 (14) 1.35 (0.80–2.27) 0.21
HIV infection 1 (2) 1 (2) 1.10 (0.27–4.45) 1.00
Chronic renal failure 15 (28) 22 (34) 0.89 (0.64–1.25) 0.52
Chronic pneumopathy 3 (6) 6 (9) 0.81 (0.5–1.33) 0.73
Bacteraemia 39 (74) 39 (60) 1.30 (0.95–1.79) 0.12
KPC infection site 0.03
Primary bloodstream infection 28 (43) 23 (43) 1.47 (0.99–2.19) 0.06
Urinary tract infections 6 (11) 20 (31) 0.64 (0.47–0.86) 0.01
Pneumonia 2 (3) 6 (11) 0.54 (0.16–1.82) 0.24
Surgical site infection 7 (13) 3 (5) 1.49 (1.94–2.36) 0.17
Intra-abdominal 5 (8) 8 (15) 0.79 (0.38–1.61) 0.48
Others 7 (11) 3 (6) 1.64 (1.04–2.61) 0.10
Renal failure 24 (45) 10 (15) 2.23 (1.29–3.83) <0.001
Time between positive culture and beginning of treatment (days) 0.02
Mean (SD) 1.6 (2.3) 2.7 (3.5)
Median (range) 1 (0–10) 2 (0–19)
Time between isolation and beginning of treatment 48 hours 39 (74) 36 (55) 1.41 (1.03–1.92) 0.04
Concomitant nosocomial infection 25 (47) 26 (40) 1.14 (0.82–1.06) 0.43
Treatment with:
Polymyxin 41 (77) 31 (48) 1.72 (1.25–2.36) 0.001
Tigecycline 8 (15) 11 (17) 0.94 (0.62–1.45) 0.79
Aminoglycoside 10 (19) 22 (34) 0.73 (0.53–1.00) 0.07
Carbapenemb 41 (77) 42 (65) 1.30 (0.94–1.79) 0.13
Monotherapy 21 (40) 36 (55) 0.75 (0.54–1.05) 0.09
Carbapenemb 6 (11) 19 (29) 0.65 (0.48–0.88) 0.02
Polymyxin 13 (24) 8 (12) 1.54 (0.87–2.73) 0.08
Aminoglycoside 1 (2) 8 (12) 0.59 (0.44–0.79) 0.04
Tigecycline 1 (2) 1 (1.5) 1.10 (0.23–4.46) 1.00
Combination therapy
Carbapenemb (in vitro resistant) + any other antimicrobial 31 (59) 23 (35) 1.54 (1.08–2.20) 0.01
Carbapenemb (in vitro susceptible) + any other antimicrobial 7 (13) 3 (5) 1.91 (0.73–5.00) 0.10
Carbapenem (total) + any other antimicrobial 38 (72) 26 (40) 2.14(1.33–3.44) 0.0006
2-drug combination 16 (30) 20 (31) 0.99 (069–1.41) 1.00
Polymyxin + carbapenemb 11 (21) 9 (14) 1.27 (0.76–2.12) 0.32
Aminoglycoside + carbapenemb 3 (6) 5 (8) 0.87 (0.5–1.53) 0.73
Aminoglycoside + tigecycline 0 2 (3) 0.54 (0.46–0.64) 0.5
Tigecycline + carbapenemb 1 (2) 1 (1.5) 1.10 (0.23–4.46) 1.00
Polymyxin + aminoglycoside 1 (2) 3 (5) 0.73 (0.4–1.31) 0.63
3-drug combination 13 (24.5) 6 (9) 1.89 (0.96–3.73) 0.03
Polymyxin + aminoglycoside + carbapenemb 10 (19) 2 (3) 3.57 (1.00–12.66) 0.006
Tigecycline + carbapenemb + polymyxin 3 (6) 2 (3) 1.39 (0.47–4.13) 0.66
Aminoglycoside + polymyxin + tigecycline 0 1 (2) 0.55 (0.46–0.65) 1.00
Aminoglycoside + carbapenemb + tigecycline 0 1 (2) 0.55 (0.46–0.65) 1.00
4-drug combination
Aminoglycoside + polymyxin + carbapenemb + tigecycline 3 (6) 3 (5) 1.11 (0.49–2.51) 1.00
Polymyxin resistancec 7/35 (20) 11/30 (37) 0.79(0.42–1.52) 0.47
Debridement or drainage of infection site 39 (74) 56 (86) 0.66 (0.39–1.13) 0.09
APACHE, Acute Physiology and Chronic Health Examination; HIV, human immunodeﬁciency virus; ICU, intensive care unit; KPC, Klebsiella pneumoniae carbapenemase; RR, relative
risk; SD, standard deviation.
aResults expressed as n (%), except where otherwise indicated.
bMeropenem or imipenem.
cResistance to polymyxin was determined by E-test or an automated method (bioMerieux Vitek 2, Hazelwood, MO, USA) for 65 isolates (resistance 2 mg/L).
179.e4 Clinical Microbiology and Infection, Volume 21 Number 2, February 2015 CMIbeen seen as suboptimal to treat bloodstream infections
because of its low serum concentrations [14] and meta-analyses
[15,16] demonstrating increased mortality. We believe that
including patients treated with tigecycline monotherapyClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectcould have led to a disadvantage in the monotherapy group.
Furthermore, another study revealed high failure rates among
patients treated with a tigecycline regimen for KPC
infections [8].ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 179.e1–179.e7
TABLE 2. Bivariate analysis of prognostic factors for 30-day mortality in patients with bacteraemic infections caused by KPC-
producing Enterobacteriaceae in three large teaching hospitals (2009–2013)
Nonsurvivorsa (n[ 39 ) Survivorsa (n [ 39) RR (95% CI) p
Age, years 0.03
Mean (SD) 59 (14.1) 50 (18.7)
Median (range) 59 (24–84) 54 (1–87)
Female sex 19 (49) 15 (39) 1.23 (0.77–1.97) 0.36
Time between admission and infection (days) 0.59
Mean (SD) 26.7(30.5) 25.4 (16.7)
Median (range) 22 (2–182) 21 (2–59)
Admission to ICU 23 (59) 17 (44) 1.36 (0.87–2.14) 0.17
APACHE II score (points) 0.57
Mean (SD) 18.4 (6.5) 17.1 (6.1)
Median (range) 17 (9–31) 16 (2–24)
APACHE II 17 points 21 (53.8) 18 (47.4) 1.14 (0.72–1.80) 0.57
Invasive procedures
Mechanical ventilation 19 (49) 11 (28) 1.59 (0.94–2.70) 0.06
Central venous catheter 24 (62) 31 (80) 0.62 (34–1.13) 0.08
Urinary catheter 23 (59) 20 (51) 1.17 (0.75–1.82) 0.49
Previous surgery 19 (49) 14 (36) 1.31 (0.81–2.11) 0.25
Organ solid transplantation 9 (23) 4 (10) 1.75 (0.75–4.08) 0.22
Hematopoietic stem cell transplantation 3 (8) 4 (10) 0.86 (0.43–1.71) 1.00
Cancer 24 (62) 19 (49) 1.29 (0.83–2.01) 0.26
Diabetes mellitus 8 (21) 5 (13) 1.36 (0.66–2.81) 0.55
HIV infection 0 0
Chronic renal failure 11 (28) 12 (31) 0.94 (0.59–1.51) 0.80
Chronic pneumopathy 3 (8) 4 (11) 0.86 (0.43–1.71) 1.00
KPC infection site 0.30
Primary bloodstream infection line-related 23 (59) 28 (72)
Pneumonia 3 (8) 1 (3)
Surgical site infection 3 (8) 1 (3)
Intra-abdominal 8 (21) 4 (10)
Others 1 (3) 1 (3)
Urinary tract infection 1 (3) 4 (10) 0.38 (0.07–2.25) 0.36
Renal failure 20 (51) 6 (15) 2.75 (1.31–5.72) 0.001
Time between isolation and beginning of treatment (days) 0.13
Mean (SD) 1.7 (2.4) 2 (1.7)
Median (range) 1 (0–10) 2 (0–5)
Time between positive culture and beginning of treatment 48 hours 28 (72) 21 (54) 1.45 (0.94–2.23) 0.10
Concomitant nosocomial infection 20 (51) 16 (41) 1.23 (0.78–1.94) 0.36
Treatment with:
Polymyxin 33 (85) 19 (49) 2.11 (1.39–3.19) 0.001
Tigecycline 6 (15) 9 (23) 0.79 (0.49–1.29) 0.39
Aminoglycoside 6 (15) 12 (31) 0.68 (0.44–1.04) 0.11
Carbapenemb 31 (80) 27 (69) 1.29 (0.82–2.02) 0.30
Monotherapy 15 (39) 19 (49) 0.81 (0.52–1.26) 0.36
Carbapenemb 4 (10) 12 (31) 0.58 (0.39–0.87) 0.05
Polymyxin 11 (28) 4 (10) 2.08 (0.88–4.96) 0.08
Aminoglycoside 0 2 (5) 0.49 (0.39–0.61) 0.49
Tigecycline 0 1(3)
Combination therapy
Carbapenemb (in vitro resistant) + any other antimicrobial 23 (59) 15 (39) 1.52 (0.95–2.43) 0.07
Carbapenemb (in vitro susceptible) + any other antimicrobial 4 (10) 0 – 0.11
Carbapenem (total) + any other antimicrobial 27(69) 15 (39) 1.93 (1.15–3.22) 0.006
2-drug combination 10 (26) 14 (36) 0.79 (0.51–1.24) 0.33
Polymyxin + carbapenemb 7 (18) 5 (13) 1.24 (0.61–2.51) 0.76
Aminoglycoside + carbapenemb 2 (5) 3 (8) 0.82 (0.39–1.74) 1.00
Aminoglycoside + tigecycline 0 2 (5) 0.49 (0.39–0.61) 0.49
Tigecycline + carbapenemb 0 1 (3) 0.49 (0.39–0.62) 1.00
Polymyxin + aminoglycoside 1 (3) 3 (8) 0.65 (0.35–1.20) 0.62
3-drug combination 11 (28) 3 (8) 2.62 (0.94–7.32) 0.04
Polymyxin + aminoglycoside + carbapenemb 8 (21) 1 (3) 4.96 (0.77–31.84) 0.03
Tigecycline + carbapenemb + polymyxin 3 (8) 1 (3) 2.05 (0.37–11.38) 0.62
Aminoglycoside + polymyxin + tigecycline 0 0
Aminoglycoside + carbapenemb + tigecycline 0 1 (3) 0.49 (0.39–0.62) 1.00
4-drug combination
Aminoglycoside + polymyxin + carbapenemb + tigecycline 3 (8) 3 (8) 1.00 (0.43–2.30) 1.00
Polymyxin resistancec 4/24 (17) 8/25(32) 0.62(026–1.45) 0.22
Debridement or drainage of infection site 29 (74) 34 (87) 0.62 (0.29–1.31) 0.25
APACHE, Acute Physiology and Chronic Health Examination; HIV, human immunodeﬁciency virus; ICU, intensive care unit; KPC, Klebsiella pneumoniae carbapenemase; RR, relative
risk; SD, standard deviation.
aResults expressed as n (%), except where otherwise indicated.
bMeropenem or imipenem.
cResistance to polymyxin was determined by E-test or an automated method (bioMerieux Vitek 2, Hazelwood, MO, USA) for 49 isolates (resistance 2 mg/L).
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aminoglycoside was signiﬁcantly associated with death in
bivariate analysis. This combination may be harmful due to
increased nephrotoxicity. The increase of adverse effects,
especially nephrotoxicity, has been demonstrated with theClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Inaddition of aminoglycoside to a β-lactam compared with
monotherapy with a β-lactam [17].
In our study, in the bivariate analysis, treatment with car-
bapenem monotherapy had a protective effect. Correlating
in vitro antimicrobial susceptibility with clinical outcomes posesfectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 179.e1–179.e7
TABLE 3. Multivariate analysis of factors associated with 30-
day mortality in patients with infections caused by KPC-
producing Enterobacteriaceae in three large teaching
hospitals (2009–2013)
OR 95% CI p
All infections (n = 118)
Renal failure at end of treatment 2.96 1.18–7.44 0.02
Urinary tract infection 0.34 0.11–1.06 0.06
Use of polymyxin 3.07 1.22–7.72 0.02
Older age 1.03 1.01–1.05 0.05
Bacteremic infections (n = 78)
Renal failure at end of treatment 3.83 1.23–11.96 0.02
Older age 1.04 1.004–1.07 0.04
Use of polymyxin 5.50 1.63–18.54 0.006
KPC, Klebsiella pneumoniae carbapenemase.
179.e6 Clinical Microbiology and Infection, Volume 21 Number 2, February 2015 CMIdifﬁculties. The reasons for the recent change in CLSI break-
points for carbapenems were: the recognition that new
breakpoints would simplify testing and eliminate need for
additional methods to detect resistance mechanisms; the new
pharmacokinetic/pharmacodynamic data; and new mechanisms
of resistance) [18]. We could speculate that, as these changes
were not backed up by clinical studies, they may not support
the clinical choices for antimicrobial therapy. In other words,
carbapenems may still be active in MIC 1–4 mg/L. This concern
was addressed in a study evaluating children with bacteraemia
caused by Enterobacteriaceae with “new MIC breakpoint”-
reduced susceptibility to ceftriaxone. They conclude that
“children with Enterobacteriaceae bacteraemia caused by strains
with reduced susceptibility (by revised breakpoints) appear to
have similar clinical outcomes when prescribed ceftriaxone,
compared with broader spectrum β-lactam regimens” [19].
We believed that the other prognostic factors observed in
our study—older age and the onset of renal failure—reﬂect
patients’ underlying disease and clinical condition and have been
found to be predictors of mortality in other studies involving
patients with infections caused by multi-drug-resistant micro-
organisms [20].
We are aware that the time to start the antibiotic regimen is
an important factor in determining outcome and hypothesized
that the counterintuitive association between early beginning of
treatment and death occurred due to the inclusion of less se-
vere infections such as urinary tract infections. In this situation,
clinicians delay treatment waiting for the results of cultures. In
the analysis of bacteremic infections, this association did not
occur.
The main weakness of our study is that it was retrospective.
Nevertheless, we used strict diagnostic criteria for infections,
used 30-day in-hospital mortality as the primary endpoint to
avoid difﬁculties in interpreting outcomes such as clinical
response, and found that the medical records provided
adequate information. Another limitation is that the clonality ofClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectthe strains and the KPC type were not evaluated. However, a
previous study showed that isolates in Brazil belong to several
different clones [21].
Our study was not designed to evaluate the efﬁcacy of
polymyxin, thus, we included cases of Serratia spp. Once results
pointed to the association between the use of polymyxin and
death, it was important that we evaluate cases caused by Ser-
ratia spp. We included six cases of S. marcescens: two received
polymyxin + meropenem + tigecycline + aminoglycoside (one
died); one received polymyxin + meropenem + tigecycline and
died; two received meropenem (one died); and one received
meropenem + aminoglycoside and died. None of the cases of
infections caused by Serratia were treated with polymyxin
monotherapy, and in combination, there were at least two
other drugs associated with polymyxin. Thus, we do not feel
that the presence of Serratia infections affected our results.
In conclusion, our study polymyxins showed suboptimal ef-
ﬁcacy, and combination therapy was not superior to mono-
therapy to treat KPC-producing Enterobacteriaceae infections.Transparency DeclarationNone of the authors have conﬂicts of interest.References[1] Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL,
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